References
- Baker GA, Jacoby A, Buck D, et al. Quality of life of people with epilepsy: A European study. Epilepsia 1997;38:353–62
- Kline Leidy N, Rentz AM, Grace EM. Evaluating health-related quality of life outcomes in clinical trials of antiepileptic drug therapy. Epilepsia 1998;39:965–77
- Selai CE, Smith K, Trimble MR. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. Seizure, 1999; 8:8–13
- Selai CE, Elstner K, Trimble MR. Is the EQ-5D sensitive to clinically defined treatment outcome in epilepsy? In Greiner W, v.d. Schulenburg J-M, Piercy J, editors. EuroQol, Plenary Meeting 1st–2nd October 1998; Discussion Papers, Centre of Health Economics and Health Systems Research, University of Hannover, 1999
- Kaiser S, Selai CE, Trimble MR. Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life. Seizure 2002;11:356–60
- Kind P, Dolan P, Gudex C, et al. Variations in population health states: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736–41
- Stavem K, Bjørnæs H, Lossius MI. Properties of the 15D and EQ-5D utility measures in a community sample of people with epilepsy. Epilepsy Res 2001;44:179–89
- EuroQol Group. EuroQol EQ-5D user guide, 1996
- Jacoby A, Baker GA, Steen N, et al. The clinical course of epilepsy and its psychosocial correlates: findings from a U.K. Community study. Epilepsia 1996;37:148–61
- Brazier J, Jones N, Kind P. Testing the validity of the EuroQol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993;2: 169–80
- Remak E, Hutton J, Peeters K, et al. Estimated impact of seizure frequency on survival in epilepsy. Poster presentation, Assoc Br Neurol, Cardiff, United Kingdom, April 2003